We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Major clinical research advances in gynecologic cancer in 2021.
- Authors
Jeong-Yeol Park; Jung-Yun Lee; Yoo-Young Lee; Seung-Hyuk Shim; Dong Hoon Suh; Jae-Weon Kim
- Abstract
In the 2021 series, we not only summarized the major clinical research advances in gynecologic oncology but also added discussions to every part, based on communications at the conference. A review of cervical cancer included adjuvant treatments such as radiation and chemoradiation (concurrent or sequential) after radical hysterectomy in early cervical cancer, and immune checkpoint inhibitors in advanced, recurrent, and metastatic disease. Ovarian cancer research included studies of secondary cytoreductive surgery in platinumsensitive recurrent ovarian cancer, and various trials of immune checkpoint inhibitors with or without vascular endothelial growth factor inhibitors and conventional chemotherapy. The rechallenge of poly (ADP-ribose) polymerase inhibitor maintenance in heavily pretreated ovarian cancer were also addressed. For uterine corpus cancer, dostarlimab (anti-programmed cell death protein 1 antibody) alone, or a tyrosine kinase inhibitor in combination with pembrolizumab for advanced, metastatic, or recurrent endometrial cancer were reviewed. The survival differences between the intensive and minimalist follow-up protocols were also described. In this review, we compared salpingectomy with delayed oophorectomy and salpingo-oophorectomy in terms of quality of life in BRCA 1 and 2 pathogenic variant carriers.
- Subjects
CHEMORADIOTHERAPY; MEDICAL research; GYNECOLOGIC cancer; VASCULAR endothelial growth factor antagonists; ADJUVANT treatment of cancer; GYNECOLOGIC oncology
- Publication
Journal of Gynecologic Oncology, 2022, Vol 33, Issue 2, p1
- ISSN
2005-0380
- Publication type
Academic Journal
- DOI
10.3802/jgo.2022.33.e43